Amplifications of FGFR1, HER2, and MET of this pathway as detected in our study may suggest therapeutic opportunities, given the emerging investigational agents or approved drugs targeting these aberrations either in SCLC or in other solid tumors 29, 30. This evidence concerns the gene FGFR1 and small cell lung carcinoma.